Ppd Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Ppd Inc (PPD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Ppd Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 5,879M vs 4,128M combined for its competitors (58.8% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+6.2% annualized vs trailing 12 months), vs decelerating (-62.4%) for its tracked peer group.
- Growth: Ppd Inc generated 26.5% revenue growth year over year in Q3 2021, vs 24.3% for its competitors combined.
- Profitability: Its 10.8% net margin compares with 9.2% for the peer group.
- Peer revenue share: Ppd Inc accounted for 80.1% of combined revenue among its tracked peer group, up from 79.8% a year earlier.
- Structure: Ppd Inc operates in the following segments: Clinical Development Services, Laboratory Services.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PPD Sales vs. its Competitors, Q3 2021
Ppd Inc reported revenue growth of 26.50 % year on year in Q3 2021, above its competitors' combined revenue growth of 24.32 %.
With a net margin of 10.84 %, Ppd Inc achieved higher profitability than its competitors (9.22 %).
Ppd Inc generated 80.07 % of the combined sales of its peer group, up from 79.79 % a year earlier.
API endpoints for this dataset
Ppd Inc vs. its Competitors, Q3 2021
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Ppd Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Ppd Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Ppd Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (32) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Ppd Inc's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 9.0% year over year, combined, vs 26.5% for Ppd Inc. Ppd Inc's share of combined industry revenue moved from 2.25% to 2.62%, a gain of 0.36 percentage points.
Ppd Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Ppd Inc | Yes | Yes | Yes | No |
| Competitors combined (4) | ||||
| High-Confidence Competitors (35) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PPD Stock Performance relative to its Competitors
PPD Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Medpace Holdings Inc | 282.9% | Outperformed |
| 2 | Quanterix Corporation | 282.9% | Outperformed |
| 3 | Evotec Se | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Ppd Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Ppd Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Ppd Inc |
16,998.96 | 5,878.94 |
 Medpace Holdings Inc |
18,553.59 | 2,838.39 |
 Evotec Se |
140.29 | 882.98 |
 Quanterix Corporation |
138.20 | 152.72 |
 Dlh Holdings Corp |
47.54 | 253.54 |
| SUBTOTAL | 35,878.57 | 10,006.56 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Ppd Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Ppd Inc's Competitors Named by the Company
Competitive relationships identified from Ppd Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Medpace Holdings Inc | Company report | 85% |
| Quanterix Corporation | Company report | 85% |
| Agilent Technologies inc | Company report | 85% |
| Twist Bioscience Corporation | Company report | 85% |
| Cytek Biosciences Inc | Company report | 85% |
| Ingersoll Rand Inc | Company report | 85% |
| Quidelortho Corp | Company report | 85% |
| Guardant Health Inc | Company report | 85% |
| Azenta Inc | Company report | 85% |
| Atlantic International Corp | Company report | 85% |
| Icon Plc | Company report | 85% |
| Iqvia Holdings Inc | Company report | 85% |
| Dlh Holdings Corp | Company report | 85% |
| Genetic Technologies Limited | Company report | 85% |
| Palisade Bio Inc | Company report | 85% |
| March GL Company | Company report | 85% |
| Greenland Exploration Limited | Company report | 85% |
| Galera Therapeutics Inc | Company report | 85% |
| 908 Devices inc | Company report | 85% |
| Quantum si Incorporated | Company report | 85% |
| Maxcyte inc | Company report | 85% |
| Sophia Genetics Sa | Company report | 85% |
| Volitionrx Limited | Company report | 85% |
| Nautilus Biotechnology Inc | Company report | 85% |
| Waters Corporation | Company report | 85% |
| Mirion Technologies Inc | Company report | 85% |
| Yeti Holdings Inc | Company report | 85% |
| Singular Genomics Systems Inc | Company report | 85% |
| Telesis Bio Inc | Company report | 85% |
| Caredx Inc | Company report | 85% |
| SQL | Company report | 85% |
| Societal Cdmo Inc | Company report | 85% |
| Auburn National Bancorporation Inc | Company report | 85% |
| Accelerate Diagnostics Inc | Company report | 85% |
| Emergent Biosolutions Inc | Company report | 85% |
| Idex Corp | Company report | 85% |
| WEED, INC. | Company report | 85% |
| Bio techne Corp | Company report | 85% |
| Harvard Bioscience Inc | Company report | 85% |
| Veracyte Inc | Company report | 85% |
| Cue Health Inc | Company report | 85% |
| Bio rad Laboratories Inc | Company report | 85% |
| Us Nuclear Corp | Company report | 85% |
| Evotec Se | Company report | 85% |
| Cryoport inc | Company report | 85% |
| Qiagen N v | Company report | 85% |
| Standard Biotools Inc | Company report | 85% |
| Charles River Laboratories International inc | Company report | 85% |
| Illumina Inc | Company report | 85% |
| Pacific Biosciences Of California Inc | Company report | 85% |
| Revvity Inc | Company report | 85% |
| Repligen Corp | Company report | 85% |
| Catalent Inc | Company report | 85% |
| Mettler toledo International Inc | Company report | 85% |
| Danaher Corporation | Company report | 85% |
| Steris Plc | Company report | 85% |
| 10x Genomics Inc | Company report | 85% |
| 3m Company | Company report | 85% |
| Enzo Biochem Inc | Company report | 85% |
| Avantor Inc | Company report | 85% |
| Guided Therapeutics Inc | Company report | 85% |
| Lantheus Holdings Inc | Company report | 85% |
| Alpha Teknova Inc | Company report | 85% |
| Varian Medical Systems Inc | Company report | 85% |
| Somalogic Inc | Company report | 85% |
| Orasure Technologies Inc | Company report | 85% |
| Neogen Corporation | Company report | 85% |
| Psychemedics Corporation | Company report | 85% |
| Steris Plc | Company report | 85% |
| Astrotech Corp | Company report | 85% |
| Becton Dickinson And Company | Company report | 85% |
| Escalon Medical Corp | Company report | 85% |
| Quest Diagnostics Inc | Company report | 85% |
| Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter ___ | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Maravai Lifesciences Holdings Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| West Pharmaceutical Services Inc | Company report | 85% |
| American Bio Medica Corporation | Company report | 85% |
| Prophase Labs Inc | Company report | 85% |
| Cardinal Health Inc | Company report | 85% |
| Nanostring Technologies Inc | Company report | 85% |
| Corning Inc | Company report | 85% |
| Catheter Precision Inc | Company report | 85% |
| Bruker Corporation | Company report | 85% |
| Biomerica Inc | Company report | 85% |
| Qhslab Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Ppd Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Ppd Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Ppd Inc | Clinical Development Services 81.41 % |
| Medpace Holdings Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Ppd Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Ppd Inc | 16,999 | - | - |
| Medpace Holdings Inc | 18,554 | 457,804 | 83,520 |
| Evotec Se | 140 | 193,933 | -25,464 |
| Quanterix Corporation | 138 | 324,238 | -261,376 |
| Dlh Holdings Corp | 48 | 110,236 | -9,377 |
| PEERS TOTAL | 18,880 | 305,207 | 19,019 |
Ppd Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Ppd Inc | North America 62.64 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Ppd Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Laboratories industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (77 companies). See the full Medical Laboratories industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 47.28 % | 33.07 % (avg) | +14.2 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | 16.44 % | -5.80 % (avg) | +22.2 pp |
| Capital Intensity (Capex / Revenue) | 2.30 % | 7.44 % (avg) | -5.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Ppd Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Laboratories industry average (77 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Laboratories industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 45.8x | 39.0x | +6.8x |
| EV / EBITDA | 20.7x | 21.1x | -0.4x |
| P/B | -28.3x | 4.4x | -32.7x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -7.68 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Ppd Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.30 % vs industry average 7.44 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Ppd Inc's dedicated Suppliers and Customers pages, not here.
Ppd Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Ppd Inc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Ppd Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+6.2% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
- A meaningful share of competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-62.4% annualized).
Methodology: see Methodology: SWOT Analysis.
Ppd Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Ppd Inc | 0.36 | 1.18 | - |
| Medpace Holdings Inc | 0.42 | 0.79 | - |
| Evotec Se | 1.14 | 2.07 | - |
| Quanterix Corporation | 0.59 | 3.18 | - |
| Dlh Holdings Corp | 0.00 | 0.88 | 1.24 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Ppd Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Ppd Inc | Q3 2021 | +26.5 % | +1,758.0 % |
| Medpace Holdings Inc | Q3 2026 | +8.5 % | +23.7 % |
| Evotec Se | Q4 2025 | +2.4 % | - |
| Quanterix Corporation | Q2 2026 | +35.4 % | - |
| Dlh Holdings Corp | Q2 2026 | -46.9 % | - |
| PEERS TOTAL | +13.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Ppd Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Ppd Inc | Q3 2021 | +19.6 % | -26.3 % |
| Medpace Holdings Inc | Q3 2026 | +6.3 % | +88.2 % |
| Evotec Se | Q4 2025 | +2.3 % | -36.1 % |
| Quanterix Corporation | Q2 2026 | +39.8 % | -87.9 % |
| Dlh Holdings Corp | Q2 2026 | -45.4 % | - |
Ppd Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Ppd Inc | 5.58% | 9.06% | - |
| Medpace Holdings Inc | 24.47% | 41.14% | 99.76% |
| Evotec Se | - | - | - |
| Quanterix Corporation | - | - | - |
| Dlh Holdings Corp | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Ppd Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Ppd Inc | 46.81 | 2.89 |
| Medpace Holdings Inc | 36.43 | 6.54 |
| Evotec Se | - | 0.16 |
| Quanterix Corporation | - | 0.90 |
| Dlh Holdings Corp | - | 0.19 |
| PEERS AVERAGE | 57.17 | 3.59 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.